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Type 2 diabetes is an epidemic disease worldwide, but it is difficult to predict its appearance in the general
population. A recent study demonstrates that circulating concentrations of a small group of essential amino
acids predict risk for diabetes, contributing to a recent resurgence of interest in these common analytes.Type 2 diabetes afflicts an estimated
24 million persons in the United States
alone. A molecular test for its prediction
could have major benefits for public
health, as it might encourage earlier and
more aggressive lifestyle interventions. A
recent study in Nature Medicine (Wang
et al., 2011) reports that elevations in
plasma levels of a small cluster of essen-
tial amino acids, including the branched-
chain amino acids (BCAAs) leucine (Leu),
valine (Val), and isoleucine (Ile) and the
aromatic amino acids phenylalanine
(Phe) and tyrosine (Tyr), are associated
with as much as a 5-fold increase in risk
for development of type 2 diabetes. This
compares to existing biomarkers such
as hemoglobin A1c and fasting glucose,
which diagnose overt diabetes, but fail
as predictive markers. The new finding
was uncovered by application of compre-
hensive metabolic profiling methods,
sometimes known as ‘‘metabolomics,’’
and highlights the potential utility of post-
genomic technologies for risk assess-
ment in chronic human diseases.
Wang and colleagues (2011) applied
an LC-MS/MS-based metabolomics ap-
proach to measure a broad array of inter-
mediary metabolites, including organic
acids, amino acids, amines, and other
small polar metabolites. Importantly,
once initial profiling implicated BCAAs
and aromatic amino acids as prognostic
variables, the authors used stable
isotope-labeled standards to confirm
their observations with a rigorously quan-
titative analytical method. They integrated
this molecular profile with pre-existing
human disease risk models by taking
advantage of data collected from theFramingham study. Using 189 samples
from subjects who developed type 2 dia-
betes and comparing them to control
subjects with similar characteristics
(BMI, caloric intake, age, and sex) who
did not develop diabetes over the same
time frame, the authors demonstrated
the predictive power of the prognostic
amino acids. They also validated this
association in an independent cohort of
subjects from the Malmo¨ Diet and Cancer
cardiovascular study. Subjects in the
upper quartile for the most prognostic
cluster of metabolites from the Framing-
ham study (Ile, Phe, and Tyr) had a 4-
fold higher risk of incident diabetes than
those in the lower quartile. Because predi-
abetic subjects in either the Framingham
or Malmo¨ cohort could be construed as
high-risk based on baseline features
such as obesity and elevated fasting
glucose, the authors also selected
a random set of 400 controls from the Fra-
mingham offspring study free of diabetes
at the time of sampling. As expected,
this random cohort had lower levels of
insulin, glucose, and lipids at baseline,
but individuals in the top quartile for levels
of the prognostic cluster of three amino
acids still had a 2-fold greater adjusted
risk of developing diabetes.
It has long been recognized that several
amino acids, including BCAAs, are
elevated in the blood of obese, insulin-
resistant, or type 2 diabetic subjects rela-
tive to healthy controls (Felig et al., 1969).
The current study and other recent work
kindle a resurgence of interest in these
analytes and place the historical observa-
tions in a new perspective. Our group
recently showed that a cluster of analytesCell Metabolisincluding BCAAs, Phe, Tyr, and products
of BCAA catabolism was associated
with insulin resistance (Newgard et al.,
2009; Huffman et al., 2009) and coronary
artery disease (CAD) (Shah et al., 2010).
Importantly, association of the BCAA-
related metabolite cluster with insulin
resistance and CAD was much stronger
than that of other analyte clusters,
including some comprised exclusively of
fatty acids and fatty acid metabolites.
Supplementation of a high-fat diet with
all three BCAAs promoted the develop-
ment of insulin resistance in rats (New-
gard et al., 2009), and infusion of a cocktail
of 18 amino acids in humans also
decreases insulin sensitivity (Tremblay
et al., 2005), suggesting that thesemetab-
olites are not merely by-products of the
disease process, but contribute to devel-
opment of metabolic dysfunction. These
findings are not universally observed,
as supplementation of Leu alone in the
drinking water has neutral or positive
effects on insulin sensitivity in diet-
induced obese mice (Zhang et al., 2007).
However, consistent with a negative role
of BCAAs in insulin-resistant states,
feeding Leu-depleted diets tomice results
in improved insulin sensitivity (Xiao et al.,
2011), and supplementation of BCAAs in
culturedmuscle cells blunts insulin action.
Other recent findings suggest that
BCAAs and related metabolites are rele-
vant to improved metabolic control in
response to therapeutic interventions.
Treatment of Zucker fatty rats with four
thiazolidinedione drugs with varying
capacities for lowering of blood glucose
revealed a strong association between
the relative efficacy of the drugs form 13, May 4, 2011 ª2011 Elsevier Inc. 491
Figure 1. Factors Modulating Essential Amino Acid Levels in Blood
The levels of essential amino acids, including the branched-chain and aromatic amino acids, are affected
by multiple factors, including diet, genetics, the gut microbiota, and metabolism. The levels of branched-
chain and aromatic amino acids in blood are now reported to help predict risk of type 2 diabetes.
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Previewsglycemic control and their ability to regu-
late a panel of genes encoding enzymes
in the BCAA catabolic pathway (Hsiao
et al., 2011). Moreover, obese subjects
undergoing gastric bypass (GBP) surgery
have a much more dramatic decline in
circulating BCAAs, Phe, and Tyr than
found in response to dietary intervention,
despite equal weight loss in the two
groups (Laferre`re et al., 2011). This finding
is significant because GBP causes
greater improvement in glucose homeo-
stasis than dietary intervention.
Thus, evidence is mounting that BCAAs
and related metabolites are associated
with insulin resistance and diabetes, play
a causal role in development of metabolic
dysfunction, and are highly responsive to
therapeutic interventions. The current
study adds the finding that BCAAs and
aromatic amino acids predict the devel-
opment of diabetes in the general popula-
tion. Further investigation will be required492 Cell Metabolism 13, May 4, 2011 ª2011to understand the relative contributions of
genetic and environmental factors to
elevations in BCAAs and aromatic amino
acids in subjects at risk for diabetes
(Figure 1). Importantly, the Framingham
study includes diet information, allowing
Wang et al. to demonstrate that the
predictive power of the amino acid cluster
survives correction for intake of protein
and essential amino acids. However,
other studies comparing obese and lean
subjects have demonstrated an increase
in protein intake in the former group (New-
gard et al., 2009), and it is also possible
that variations in intestinal bacteria (the
‘‘gut microbiota’’) contribute via their
ability to synthesize essential amino acids
that are not synthesized in human cells.
The advent of ‘‘deep sequencing’’ tech-
nologies and their application to large
human cohorts will provide a fresh oppor-
tunity to test for associations of amino
acid-metabolizing genes with insulinElsevier Inc.resistance or diabetes. Additional studies
employing a time-to-event analysis in
a full population-based cohort will also
be necessary to elucidate the incremental
value of the amino acid signature to
clinical models of risk. Nevertheless, the
molecular profile identified by Wang
et al. (2011) appears as robust as any
that has emerged for detection of dia-
betes risk to date. Its integration with
other predictive signatures and clinical
models could significantly enhance our
ability to diagnose diabetes before the
appearance of clinical disease.
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